Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaFlavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaFlavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaAlvocidib in Treating Patients With Locally Advanced or Metastatic Solid TumorsFlavopiridol in Treating Patients With Recurrent Prostate CancerIrinotecan and Flavopiridol in Treating Patients With Advanced Liver CancerCombination Chemotherapy in Treating Patients With Refractory or Recurrent Solid TumorsBortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsLenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaAlvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaA Phase 1b/2 Study of Alvocidib Plus Decitabine in Patients With MDSA Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid LeukemiaDepsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumAlvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (2006-10-31)Combination Chemotherapy in Treating Patients With Advanced Solid Tumors (2002-07-31)Combination Chemotherapy in Treating Patients With Advanced Solid Tumors (2002-04-30)Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors (2002-05-31)Combination Chemotherapy in Treating Patients With Advanced Cancer (2001-05-31)
P4844
Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the ratFlavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells.Induced growth inhibition, cell cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem cells by flavopiridol.Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA.Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administrationMyeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapyAlvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
P921
Q61915530-1AD4FD69-40AB-432C-A79B-699CB26F9E70Q61924627-F68A340C-F098-42E2-84F7-3F16CDB33C91Q61938120-AF348359-0AA0-41DC-AF50-5FF58F93052CQ62105023-5C12C2DE-D705-43FF-AB0C-F405E569979FQ62105031-6ADC8D9D-51CD-4A6C-8A03-A2F3A2C559A4Q62110176-F2569BE4-9A83-4DC5-A85C-47E7C6D920FEQ62110422-BFA47FFA-1F94-4CF9-971D-7418FAAE963BQ62110995-C5454E96-C570-401F-A38A-7384C89DFB24Q62111098-4A123487-61E1-48E4-B3ED-BA7DA2794AFCQ63063384-0A8A671E-2C14-4D78-8B73-A59F5F556B2DQ63334996-BBE1A4F8-CF3F-4E61-86BC-FAAEBBEA24C1Q63394928-CD247039-783F-4EB1-9E82-68E6E5D716CEQ63399200-E7A7FB0A-A2D2-4FB6-A90A-407A6781EE20Q63804967-3BD8DFB1-D10C-421A-88CF-47688B749999Q86244343-17613B96-6292-4C81-9464-75152029DF33Q86254107-006CBA8F-63F6-477F-B538-96C344EB6C33Q86254138-91C5C33D-6612-4605-8525-F11AD6DB542FQ86254312-84415D81-4574-4A73-B77A-ECDA8EA92DF5Q86255006-045970DB-D86A-4595-AA91-C8BD1C814247
P4844
Q28342649-A36D8292-8BBE-43BC-9849-8C700714F38FQ28370556-0014A482-E04B-4EC9-BDFA-923BD7290E62Q33889556-A6A4C1DB-9EB0-4C7C-A690-3A241840B813Q34114592-1FB227DA-234C-4BBF-895E-53DB5CA540B6Q34738960-D4B6DAA7-1B4D-40AA-B2DE-D6C85D024709Q36709001-212B2B17-6F94-4DD9-9A35-1442C929FAFEQ38621659-A5E613B7-70FB-47E2-9B32-AD989F6C040BQ38873112-D6F5F7CB-574A-4D8D-920A-F0F60B536C2FQ38888994-A02CCCCB-412A-43F7-A4D3-27E214A7AC89Q38916209-77D5CDF2-3620-40AE-802C-DAD229B6530DQ38944385-227529B4-E3A2-428A-8CE8-7285E001AB2AQ38957130-27B1573F-32C9-434F-A08E-E1C53D6C5D2FQ38966541-CEE76EEB-18BA-42D5-AA16-6072E77E050EQ41128761-9B9C2A65-50AE-4B86-9355-9D82C3C2DE9CQ42283108-188DEC84-18AC-43D8-BBCA-68DC188C6215Q55036064-89B19436-C6A2-4816-9DC3-A97483D4CDA5Q58290188-25B7900B-A4CA-4D3E-B874-AE442F25ECE0Q64265730-76F1C011-D478-44D9-8F13-FDC5295C10B8Q65383726-14627133-DABD-483F-AFD8-251E2A323F1C
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Alvocidib
@sh
Alvocidib
@sr
alvocidib
@en
альвоцидиб
@ru
الووسیدیب
@azb
الووسیدیب
@fa
アルボシジブ
@ja
type
label
Alvocidib
@sh
Alvocidib
@sr
alvocidib
@en
альвоцидиб
@ru
الووسیدیب
@azb
الووسیدیب
@fa
アルボシジブ
@ja
altLabel
(-)-cis-5,7-dihydroxy-2-(2-chl ...... ridinyl)-4H-1-benzopyran-4-one
@en
2-(2-chlorophenyl)-5,7-dihydro ...... peridin-4-yl]-4H-chromen-4-one
@en
Alvocidib freebase
@en
Alvocidib
@en
Flavopiridol
@en
HL 275
@en
HMR 1274
@en
HMR 1275
@en
HMR-1274
@en
L 86-8275
@en
prefLabel
Alvocidib
@sh
Alvocidib
@sr
alvocidib
@en
альвоцидиб
@ru
الووسیدیب
@azb
الووسیدیب
@fa
アルボシジブ
@ja
P2868
P638
P486
P592
P6366
P661
P662
P665
P683
P2017
CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
P2067
P2275
alvocidib
@en
P231
146426-40-6
P233
CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O
P234
1S/C21H20ClNO5/c1-23-7-6-12(17 ...... 7H,6-7,10H2,1H3/t12-,17+/m0/s1
P235
BIIVYFLTOXDAOV-YVEFUNNKSA-N
P274
C₂₁H₂₀ClNO₅
P3117
DTXSID20904970